Amarin Corp Plc (AMRN)

[ziploc_1]

One...QUOTE ". He(i.e. the pharmacist) stated he did not know what I was taking if for and when the generic states it is an exact replacement that he has no other choice then to change me to the generic."

If this is the case, Amarin needs to introduce their authorized generic Vascepa ASAP, even before their legal cases against Hikma are adjudicated. If Amarin prevails in these cases, it can withdraw their authorized generic Vascepa from the market...This will have several advantages:

1.it will give patients real Vascepa instead of adulterated gV
2. patients who are encouraged by the many benefits of the real Vascepa, will be more inclined to ask for it
3.it will reduce profits for Hikma
4. the low volume of sales for Hikma will make Hikma's API prices even higher
6. it will satisfy Amarin's existing commitments to buy a large amount of supply of API and finished product
7. it will encourage Hikma's current suppliers to switch to supplying Amarin
8. it help to keep Amarin cash flow positive while legal cases are in progress.